Phase 2 Prostate Cancer Trial, Recruiting NCT06615752 Sponsor: Charles Drew University of Medicine and Science Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT06615752
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to sign a consent form and agree to follow all study procedures for the full duration of the trial
  • You are male and 18 years of age or older
  • You have been diagnosed with prostate cancer that has spread to other parts of the body (metastatic prostate cancer)
  • Your prostate cancer has continued to grow or spread while you were receiving treatment to lower testosterone (either through medication or surgery)
  • Your prostate cancer has continued to grow or spread even while taking certain hormone-blocking medications (such as enzalutamide, apalutamide, darolutamide, or abiraterone acetate)
  • Your doctor has already decided that you should start a chemotherapy treatment called docetaxel along with a steroid called prednisone
  • Your blood counts are at an acceptable level, meaning your immune cells and platelets are high enough (confirm with trial site)
  • Your liver is functioning well enough, based on blood test results (confirm with trial site)
  • Your kidneys are functioning well enough, based on blood test results (confirm with trial site)
  • You are expected to live for at least 6 months or more
  • You are willing to stop drinking tea or taking quercetin supplements during the study, except for the green tea extract and quercetin provided as part of the trial

Who may not be able to join:

  • You have previously received chemotherapy or radiation therapy to treat your metastatic prostate cancer
  • You have another health condition that would make it unsafe for you to take the chemotherapy drug docetaxel with prednisone
  • You currently have an ongoing problem with alcohol abuse
  • You have a serious medical or mental health condition that could make participating in this study difficult or unsafe
  • You have had an allergic reaction to tea, tea products, or quercetin supplements in the past
  • You have allergies to multiple foods or nutritional supplements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Piwen Wang, PhD, Charles Drew University of Medicine and Science

Phone: 3235634999

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Charles Drew University of Medicine and Science
Registry
ClinicalTrials.gov
Start date
1 October 2026
Est. completion
1 April 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Efficacy evaluated with blood prostate specific antigen (PSA) level

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov